U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07282808) titled 'Focal or Radical Therapy: a Lesion-based Molecular Evaluation in Prostate Cancer' on Nov. 20.
Brief Summary: Focal therapy (FT) is a new approach to treating localized prostate cancer. Instead of treating the entire prostate, it targets only the cancerous areas while preserving healthy tissue. This helps reduce side effects like urinary, sexual, and bowel problems.
In a prospective observational expansion of our phase II clinical trial (ProAMFocal), 80% of patients with small, localized prostate cancers treated with FT had no cancer recurrence at one year, and 70% at 3 years after treatment. We studied the genetic makeup of each ca...